A major downgrade, a billion-dollar pipeline gamble, and a patent war--Exelixis investors brace for a wild ride.

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of ...

Truist Securities increased its price target for Exelixis (NASDAQ:EXEL) shares to $43.00, up from the previous target of $42.00, while reaffirming a Buy rating on the stock. The new target represents ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

Stifel analysts maintained a Hold rating with a $30.00 price target on Exelixis stock (NASDAQ:EXEL), currently trading at $33.32 with a market capitalization of $9.5 billion. According to InvestingPro ...

Park Avenue Securities LLC acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and ...

On Friday, Exelixis Inc (EXEL) stock saw a decline, ending the day at $32.38 which represents a decrease of $-1.75 or -5.13% from the prior close of $34.13. The stock opened at $33.49 and touched a ...

Merit Financial Group LLC purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the fourth ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $34.13 which represents a slight increase of $1.25 or 3.80% from the prior close of $32.88. The stock opened at $33 and touched a low ...

Exelixis (NASDAQ:EXEL) is down 5.95% to $32.10 as of 11:04 AM ET Friday, following a downgrade from Oppenheimer, which cut its rating to Perform from Outperform due to concerns over drug ...